1070 related articles for article (PubMed ID: 33573850)
21. Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis.
Zawawi A; Naser AY; Alwafi H; Minshawi F
Front Immunol; 2021; 12():666223. PubMed ID: 34046036
[TBL] [Abstract][Full Text] [Related]
22. Capturing Cytokines with Advanced Materials: A Potential Strategy to Tackle COVID-19 Cytokine Storm.
Meng QF; Tian R; Long H; Wu X; Lai J; Zharkova O; Wang JW; Chen X; Rao L
Adv Mater; 2021 May; 33(20):e2100012. PubMed ID: 33837596
[TBL] [Abstract][Full Text] [Related]
23. Phytotherapy for treatment of cytokine storm in COVID-19.
Sapra L; Bhardwaj A; Azam Z; Madhry D; Verma B; Rathore S; Srivastava RK
Front Biosci (Landmark Ed); 2021 Apr; 26(5):51-75. PubMed ID: 34027650
[TBL] [Abstract][Full Text] [Related]
24. The Many Faces of JAKs and STATs Within the COVID-19 Storm.
Grant AH; Estrada A; Ayala-Marin YM; Alvidrez-Camacho AY; Rodriguez G; Robles-Escajeda E; Cadena-Medina DA; Rodriguez AC; Kirken RA
Front Immunol; 2021; 12():690477. PubMed ID: 34326843
[TBL] [Abstract][Full Text] [Related]
25. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
26. Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
Ghasemzadeh M; Ghasemzadeh A; Hosseini E
Hum Immunol; 2022 Jan; 83(1):86-98. PubMed ID: 34583856
[TBL] [Abstract][Full Text] [Related]
27. Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities.
Almada L; Angiolini SC; Dho ND; Dutto J; Gazzoni Y; Manzone-Rodríguez C; Marín C; Ponce NE; Arroyo DS; Quiróz JN; Iribarren P; Cerbán FM; Morón G; Amezcua Vesely MC; Cervi L; Chiapello LS; Fozzatti L; Icely PA; Maccioni M; Montes CL; Motrán CC; Rodríguez-Galán MC; Stempin CC; Viano ME; Mena C; Bertone M; Abiega CD; Escudero D; Kahn A; Caeiro JP; Maletto BA; Acosta Rodríguez EV; Gruppi A; Sotomayor CE
Front Immunol; 2023; 14():1111797. PubMed ID: 36817433
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets.
Kumar V
Int Immunopharmacol; 2020 Dec; 89(Pt B):107087. PubMed ID: 33075714
[TBL] [Abstract][Full Text] [Related]
29. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19.
Attiq A; Yao LJ; Afzal S; Khan MA
Int Immunopharmacol; 2021 Dec; 101(Pt B):108255. PubMed ID: 34688149
[TBL] [Abstract][Full Text] [Related]
30. T cell immunobiology and cytokine storm of COVID-19.
Luo XH; Zhu Y; Mao J; Du RC
Scand J Immunol; 2021 Mar; 93(3):e12989. PubMed ID: 33113222
[TBL] [Abstract][Full Text] [Related]
31. Possible mechanisms responsible for acute coronary events in COVID-19.
Sheth AR; Grewal US; Patel HP; Thakkar S; Garikipati S; Gaddam J; Bawa D
Med Hypotheses; 2020 Oct; 143():110125. PubMed ID: 32763657
[TBL] [Abstract][Full Text] [Related]
32. Immune Profiling of COVID-19 in Correlation with SARS and MERS.
Khalil BA; Shakartalla SB; Goel S; Madkhana B; Halwani R; Maghazachi AA; AlSafar H; Al-Omari B; Al Bataineh MT
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062368
[TBL] [Abstract][Full Text] [Related]
33. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.
Choudhary S; Sharma K; Silakari O
Microb Pathog; 2021 Jan; 150():104673. PubMed ID: 33278517
[TBL] [Abstract][Full Text] [Related]
34. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".
Giuliani C; Bucci I; Napolitano G
Med Hypotheses; 2021 Jan; 146():110473. PubMed ID: 33385879
[TBL] [Abstract][Full Text] [Related]
35. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
36. What Is a Cytokine Storm and Should It Matter to Me?
Simkin J; Strange T; Leblanc N; Rivera JC
J Am Acad Orthop Surg; 2021 Apr; 29(7):297-299. PubMed ID: 33443384
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel.
Napodano C; Pocino K; Stefanile A; Marino M; Miele L; Gulli F; Basile V; Pandolfi F; Gasbarrini A; Rapaccini GL; Basile U
Scand J Immunol; 2021 Mar; 93(3):e12977. PubMed ID: 32931622
[TBL] [Abstract][Full Text] [Related]
38. Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19.
Paolini A; Borella R; De Biasi S; Neroni A; Mattioli M; Lo Tartaro D; Simonini C; Franceschini L; Cicco G; Piparo AM; Cossarizza A; Gibellini L
Cells; 2021 Jun; 10(7):. PubMed ID: 34201847
[TBL] [Abstract][Full Text] [Related]
39. The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.
Zimecki M; Actor JK; Kruzel ML
Int Immunopharmacol; 2021 Jun; 95():107571. PubMed ID: 33765614
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 Pulmonary and Olfactory Dysfunctions: Is the Chemokine CXCL10 the Common Denominator?
Oliviero A; de Castro F; Coperchini F; Chiovato L; Rotondi M
Neuroscientist; 2021 Jun; 27(3):214-221. PubMed ID: 32659199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
